Insider Buying: Vaxart, Inc. (NASDAQ:VXRT) Insider Purchases 100,000 Shares of Stock

Vaxart, Inc. (NASDAQ:VXRT) insider Steven Lo acquired 100,000 shares of the company’s stock in a transaction on Monday, May 19th. The shares were bought at an average cost of $0.49 per share, with a total value of $49,000.00. Following the acquisition, the insider now directly owns 100,000 shares in the company, valued at approximately $49,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Vaxart Trading Down 1.0%

Shares of VXRT stock traded down $0.01 on Monday, reaching $0.50. The company’s stock had a trading volume of 1,470,062 shares, compared to its average volume of 2,424,511. The stock’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.57. Vaxart, Inc. has a 1 year low of $0.29 and a 1 year high of $1.07. The company has a market capitalization of $114.07 million, a price-to-earnings ratio of -1.22 and a beta of 1.27.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The business had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $2.85 million. Equities research analysts forecast that Vaxart, Inc. will post -0.39 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp increased its stake in Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares during the last quarter. Squarepoint Ops LLC lifted its position in Vaxart by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock worth $342,000 after buying an additional 251,789 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Vaxart in the fourth quarter worth $129,000. Virtu Financial LLC purchased a new position in Vaxart during the first quarter worth $56,000. Finally, Silverarc Capital Management LLC increased its position in Vaxart by 7.8% during the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock valued at $714,000 after acquiring an additional 77,782 shares during the last quarter. Institutional investors own 18.05% of the company’s stock.

Analysts Set New Price Targets

Separately, B. Riley decreased their target price on Vaxart from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.